-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind welcomes Trump executive order speeding FDA review of breakthrough psychedelic therapies

PUBT·04/20/2026 20:03:44
Listen to the news
Clearmind welcomes Trump executive order speeding FDA review of breakthrough psychedelic therapies
  • Clearmind welcomed President Donald Trump’s April 18, 2026 executive order directing FDA to prioritize reviews for certain breakthrough-designated psychedelic therapies.
  • Executive order also expands patient access pathways, which Clearmind framed as a catalyst for veteran mental health care.
  • Clearmind highlighted February 2026 bipartisan House bill H.R. 7091 as a milestone that explicitly named its MEAI compound for potential VA-supported trials.
  • Company said it is advancing FDA-authorized Phase I/IIa trials of lead candidate CMND-100 for alcohol use disorder at Yale School of Medicine and Johns Hopkins University.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604201603PRIMZONEFULLFEED9693389) on April 20, 2026, and is solely responsible for the information contained therein.